Broadcast Date: December 6, 2022
Time: 8:00 am PT, 11:00 am ET, 17:00 CET
Resins with protein A ligands have been the workhorse of monoclonal antibody capture, as their application typically results in >95% purity. In addition, protein A media effectively reduces most host cell protein and DNA. However, it is increasingly recognized in the industry that resin-based chromatography matrices are associated with drawbacks, such as value-added pricing of protein A media due to limited supplier options, lower productivity (around 10-20 g/L/h in single column batch mode), which additionally leads to higher cost, ineffective lifetime utilization (particularly pre-commercial), and higher risk. An alternative approach is to intensify this step by employing membrane-based rapid cycling chromatography (RCC), which relies on an open pore matrix and convective mass transfer to reduce cycle times significantly. Innovative solutions such as RCC provide a shorter return on investment times, less risk for bioburden events, and substantially shorter process development times.
This GEN webinar, our expert presenters will tell us much more about how membrane-based RCC can improve bioprocessing economics. Moreover, we will learn how the “one-batch, one-membrane approach” reduces risk and minimizes hands-on time and how critical quality attributes and scalability are maintained while flexibility is improved using Sartobind® Rapid A resin.
A live Q&A session followed the presentation, offering a chance to pose questions to our expert panelists.
Produced with support from: